Neuropeptide specificity of prostaglandin E2-induced activation of splenic and renal sympathetic nerves in the rat.
Sympathetic activation occurs rapidly following intracerebroventricular (icv) injection of prostaglandin E2(PGE2). This study examined whether neuropeptides mediate PGE2-induced sympathetic nerve activation in urethane/chloralose-anesthetized Sprague-Dawley rats. Animals were pretreated (20.0 microg, icv) with the following receptor antagonists; CRF ([D-Phe12,Nle21,38,Calpha-MeLeu37]CRF12-41), AVP-V1 (Des-Gly-[Phaa1, D-Tyr(Et)2,Lys6,Arg8]-vasopressin), or OT (OT+V1, [d(CH2)5,Tyr(Me)2,Orn8]-vasotocin) followed 20 min later by PGE2 (2.0 microg, icv). Pretreatment with the CRF antagonist attenuated the increase in renal nerve activity induced by PGE2 when measured 10 and 30 min post-injection. PGE2-induced renal nerve activity was also inhibited at both time points by the AVP antagonist and, to a similar extent, the OT antagonist. The AVP antagonist did not effect splenic nerve responses to PGE2 whereas the CRF antagonist produced an incomplete and transient reduction in PGE2-induced activation of the splenic nerve. However, the OT antagonist completely blocked the activation of the splenic nerve after central injection of PGE2. ICV injections of AVP and OT produced immediate changes in splenic and renal nerve activity whereas CRF failed to alter the activity of either nerve in anesthetized or conscious animals. Thus, PGE2 acts through neuropeptide-specific pathways to initiate sympathetic outflow and OT is a specific component of the sympathetic pathway innervating the spleen.
MacNeil
Brian J
BJ
School of Medical Rehabilitation, University of Manitoba, R106-771 McDermot Avenue, Winnipeg, Man., Canada R3E 0T6. macniel@scrc.umanitoba.ca
Jansen
Arno H
AH
Greenberg
Arnold H
AH
Nance
Dwight M
DM
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001921:Brain / Q000502:physiology; D015232:Dinoprostone / Q000008:administration & dosage / Q000502:physiology*; D006727:Hormone Antagonists / Q000494:pharmacology; D007276:Injections, Intraventricular; D007668:Kidney / Q000294:innervation*; D008297:Male; D015213:Neuroimmunomodulation / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D018045:Receptors, Oxytocin / Q000037:antagonists & inhibitors; D013154:Spleen / Q000294:innervation*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology*
D065092:Antidiuretic Hormone Receptor Antagonists; D006727:Hormone Antagonists; D018019:Receptors, Corticotropin-Releasing Hormone; D018045:Receptors, Oxytocin; D015232:Dinoprostone